AI Engines For more Details: Perplexity Kagi Labs You
Muscle Spasm Relief: Tizanidine acts as a centrally acting alpha-2 adrenergic agonist, which means it works in the central nervous system to inhibit certain neurotransmitters' release, resulting in muscle relaxation. It is effective in reducing muscle spasms and associated pain.
Multiple Sclerosis (MS): Tizanidine is often prescribed to individuals with multiple sclerosis who experience muscle stiffness and spasms. It helps alleviate these symptoms, improving mobility and quality of life for MS patients.
Spinal Cord Injury: Muscle spasms are common in individuals with spinal cord injuries. Tizanidine can help manage these spasms, allowing for better movement and function.
Neurological Disorders: Tizanidine may also be used to treat muscle spasms associated with other neurological conditions such as cerebral palsy, stroke, or traumatic brain injury.
Off-Label Uses: In addition to its approved indications, tizanidine may be prescribed off-label for conditions such as fibromyalgia or chronic pain syndromes where muscle spasms contribute to discomfort.
Dosage and Administration: Tizanidine is usually taken orally, typically two to three times daily. The dosage may be adjusted based on individual response and tolerance. It's important to follow the prescribed dosage and administration instructions provided by a healthcare professional.
Side Effects: Common side effects of tizanidine may include drowsiness, dizziness, dry mouth, weakness, fatigue, and gastrointestinal disturbances such as nausea or constipation. These side effects are often dose-dependent and may improve over time. However, severe side effects such as liver toxicity or allergic reactions are rare but possible.
Drug Interactions: Tizanidine may interact with other medications, including certain antibiotics, antidepressants, antihypertensives, and opioids. Concurrent use of these drugs may potentiate the sedative effects of tizanidine or increase the risk of adverse reactions. It's essential to inform healthcare providers about all medications being taken to avoid potential interactions.
Monitoring: Patients taking tizanidine may require periodic monitoring of liver function, especially during long-term therapy or in those with pre-existing liver conditions. Blood pressure monitoring is also recommended due to the potential for tizanidine to cause hypotension (low blood pressure).
Contraindications: Tizanidine is contraindicated in individuals with a history of liver disease or significant hepatic impairment. It should be used with caution in patients with impaired renal function, as dosage adjustments may be necessary.
Pregnancy and Lactation: The safety of tizanidine during pregnancy or breastfeeding has not been established. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using tizanidine.
Overdose: Overdose of tizanidine can result in severe central nervous system depression, respiratory depression, hypotension, or coma. If an overdose is suspected, medical attention should be sought immediately.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 2.2 | 0.3 | 6.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.6 | 1.1 | 0.45 |
| Allergies | 2.2 | 0.7 | 2.14 |
| Allergy to milk products | 0.6 | 0.6 | 0 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 2.1 | 3.1 | -0.48 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 1.3 | |
| Ankylosing spondylitis | 2.4 | 0.6 | 3 |
| Anorexia Nervosa | 0.7 | 1.8 | -1.57 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 3.6 | 1.8 | 1 |
| Atherosclerosis | 0.9 | 1 | -0.11 |
| Atrial fibrillation | 2.2 | 0.6 | 2.67 |
| Autism | 3.9 | 3.7 | 0.05 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.6 | 1.1 | -0.83 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Cancer (General) | 0.6 | 0.9 | -0.5 |
| Carcinoma | 2.4 | 1.9 | 0.26 |
| Celiac Disease | 1.2 | 2.6 | -1.17 |
| Cerebral Palsy | 1.2 | 1 | 0.2 |
| Chronic Fatigue Syndrome | 2.1 | 2.3 | -0.1 |
| Chronic Kidney Disease | 2.1 | 1.1 | 0.91 |
| Chronic Lyme | 0.4 | 0.8 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.4 | -1.33 |
| Chronic Urticaria (Hives) | 0.6 | 0.6 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1 | -2.33 |
| Cognitive Function | 1.7 | 1.4 | 0.21 |
| Colorectal Cancer | 2.1 | 1.4 | 0.5 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.6 | 1.5 | -1.5 |
| COVID-19 | 3.5 | 4.2 | -0.2 |
| Crohn's Disease | 3.3 | 2.8 | 0.18 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.4 | -1.4 | |
| deep vein thrombosis | 1.1 | -1.1 | |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 4 | 4.3 | -0.07 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 0.7 | -0.17 |
| Endometriosis | 1.6 | 1.4 | 0.14 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.3 | 0.7 | 0.86 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 2.1 | 0.6 | 2.5 |
| Functional constipation / chronic idiopathic constipation | 2.2 | 1.3 | 0.69 |
| gallstone disease (gsd) | 1 | 0.8 | 0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.7 | -1.33 |
| Generalized anxiety disorder | 1 | 1.3 | -0.3 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 1.2 | 2.7 | -1.25 |
| Gulf War Syndrome | 0.4 | 0.3 | 0.33 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.1 | 0.9 | 1.33 |
| Heart Failure | 1.1 | 1 | 0.1 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.2 | 0.7 | -2.5 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.2 | 3.2 | -0.45 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.2 | 0.3 | 3 |
| IgA nephropathy (IgAN) | 0.9 | 1.7 | -0.89 |
| Inflammatory Bowel Disease | 3.6 | 3.3 | 0.09 |
| Insomnia | 1.6 | 1.8 | -0.13 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.4 | 0.3 | 0.33 |
| Irritable Bowel Syndrome | 2.8 | 2.6 | 0.08 |
| ischemic stroke | 1.7 | 0.8 | 1.13 |
| Liver Cirrhosis | 3.8 | 2.3 | 0.65 |
| Long COVID | 2.8 | 3.6 | -0.29 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.7 | -0.7 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.3 | 0.8 | -1.67 |
| ME/CFS without IBS | 0.8 | 1.3 | -0.63 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.5 | 1.2 |
| Metabolic Syndrome | 3.2 | 4.2 | -0.31 |
| Mood Disorders | 3.6 | 3.3 | 0.09 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 2.3 | 1.8 | 0.28 |
| Multiple system atrophy (MSA) | 0.7 | 0.4 | 0.75 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 2.5 | -7.33 |
| Neuropathy (all types) | 0.7 | 0.9 | -0.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 2.5 | 0.32 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 4.7 | 3.9 | 0.21 |
| obsessive-compulsive disorder | 1.9 | 1.9 | 0 |
| Osteoarthritis | 1 | 0.9 | 0.11 |
| Osteoporosis | 1.4 | 1.3 | 0.08 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3 | 3.5 | -0.17 |
| Polycystic ovary syndrome | 1.7 | 1.8 | -0.06 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.6 | 1 |
| Primary sclerosing cholangitis | 1 | 0.3 | 2.33 |
| Psoriasis | 1.3 | 0.8 | 0.63 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 2.7 | 0.37 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 3.1 | 1.8 | 0.72 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 1.2 | 1.4 | -0.17 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.4 | 1.25 |
| Stress / posttraumatic stress disorder | 1.7 | 1.6 | 0.06 |
| Systemic Lupus Erythematosus | 1.6 | 2 | -0.25 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1.3 | 2.6 | -1 |
| Type 2 Diabetes | 3.2 | 2.9 | 0.1 |
| Ulcerative colitis | 2.4 | 2.7 | -0.13 |
| Unhealthy Ageing | 2.1 | 1.1 | 0.91 |
| Vitiligo | 1.2 | 0.3 | 3 |
